NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Somatrogon (Primary)
- Indications Dwarfism; Growth disorders; Noonan syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
- Focus Therapeutic Use
- Acronyms NordiNet IOS
- Sponsors Novo Nordisk
- 05 Aug 2017 Results (n=172) assessing long term efficacy and safety published in the European Journal of Endocrinology.
- 03 Feb 2017 Status changed from recruiting to completed.
- 01 Jun 2016 New trial record